|Bid||125.0500 x 300|
|Ask||125.3500 x 100|
|Day's Range||120.8500 - 125.8500|
|52 Week Range||28.3500 - 127.0200|
|PE Ratio (TTM)||-15.36|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you are looking to invest in Puma Biotechnology Inc’s (NASDAQ:PBYI), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
Biotech stocks have been a favorite of fast money, too, since it moves faster than the Standard & Poor’s 500 – in both directions. Some stocks, such as Vertex Pharmaceuticals (NASDAQ:VRTX), are already up triple-digit percentages this year. Or, they may be emerging from long trading ranges where uncertainty previously ruled.
On a per-share basis, the Los Angeles-based company said it had a loss of $2.10. Losses, adjusted for stock option expense, came to $1.38 per share. The results surpassed Wall Street expectations. The ...
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
After Puma Biotech's recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?
Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.
Puma stock rocketed to a 22-month high Tuesday on takeover speculation after the FDA approved the firm's breast cancer drug, Nerlynx.
Puma Biotechnology Inc (NASDAQ:PBYI) has won FDA approval for its lead candidate Nerlynx (neratinib), sending shares up 9% in Tuesday's trading session. The drug treats breast cancer patients that are HER2 positive and reduces the risk of a relapse. According to the NCI, nearly 40,000 breast cancer patients across the United States are HER2-positive, accounting for 15% of all cancer patients.
Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the agency ...
Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.
Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.
Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.
The American Society of Clinical Oncology’s annual meeting ended Tuesday. The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings ...
Tesla shares could rise 26%, Pacific Crest said, assuming that Model 3 demand will top estimates. Analysts raised price targets on Puma Biotech, Microchip and Ulta Beauty.
This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day
Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.